Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis remains poor. Therefore, the development of novel therapeutic strategies is urgently needed, and immunotherapy utilizing anti-programmed death 1/-pro- 
Marked expression of PD-L1 has been reported in various types of human cancer and tumor-infiltrating immune cells. [5] [6] [7] Indeed,
we and others have recently demonstrated that PD-L1 expression on tumors inhibits the effector phase of CTL function, and blockade of PD-L1 can augment the tumor-specific CTL response in vitro. 3, 4, [8] [9] [10] Moreover, several clinical trials on the inhibition of PD-1/PD-L1 interaction with therapeutic mAb induced significant and durable responses in several types of refractory tumors, [11] [12] [13] [14] [15] suggesting that the PD-1 and PD-L1 interaction might have a pivotal role in anti-tumor immunity.
Programmed death ligand-1 on tumor cells is often upregulated within the tumor microenvironment. 16, 17 Several mechanisms for the upregulation of PD-L1 on tumor cells, which include epigenetic factors, oncogenic signaling and acquired immune responses, have been proposed. 18 Constitutive oncogenic signaling has been reported to induce PD-L1 expression on tumor cells either through the phosphatidylinositol-3-kinase-protein kinase B (PI3K-AKT) pathway or signal transducer and activator of transcription (STAT) 3 signaling. 19, 20 Acquired immune response is also considered to manifest through PD-L1 upregulation on tumor cells by endogenous anti-tumor immunity factors in the tumor microenvironment, such as interferon gamma (IFN-c) produced by tumor infiltrating lymphocytes (TIL). 21 Furthermore, it has recently been shown that the microRNA-200/zinc-finger E-box-binding homeobox 1 (ZEB-1) axis, which is closely related to the epithelialmesenchymal transition (EMT) conversion, could regulate PD-L1 expression. 22 However, there is still limited information on how PD-L1 on tumor cells is upregulated in the tumor microenvironment, especially in the human tumor system.
Gastric cancer (GC) is the fourth most common malignancy in the world and second leading cause of cancer death worldwide, accounting for 723 000 deaths annually. 23 Despite various treatments such as surgical resection combined with chemotherapy, the prognosis for patients with advanced GC remains poor. The 5-year overall survival rates of patients with pathological stage IV disease who underwent resection between 2001 and 2007 is 16.4% in Japan. 24 Previous studies have reported that PD-L1 is expressed in 42% of GC tissue, and is correlated with tumor size, invasion, lymph node status and patient survival. 25 In a clinical trial using the anti-PD-1 mAb, pembrolizumab, for GC patients who were refractory to standard chemotherapy, an overall response of 22% and 6-month progression free survival of 26% were reported by Muro et al. 26 Utilization of immunotherapy with anti-PD-1/-PD-L1 mAb is, therefore, an attractive approach for GC.
In this study, we examined the mechanisms of PD-L1 regulation with a particular focus on IFN-c, and how PD-L1 is related to tumor-specific CTL function using a panel of human solid tumors.
Furthermore, we evaluated in detail the relationship between PD-L1 expression on tumor cells and types of TIL by immunohistochemistry (IHC) in surgically resected specimens of GC.
| MATERIALS AND METHODS

| Tumor cell lines
The 30 cell lines used in this study are summarized in Table S1 . All cell lines except for HEK293T were cultured in RPMI-1640 containing L-glutamine (Invitrogen, Carlsbad, CA, USA) with 5% FCS (Invitrogen) and 1% Penicillin-Streptomycin (Sigma-Aldrich, St. Louis, MO, USA).
The HEK293T cell line was cultured in DMEM (Invitrogen) with 10% FCS (Invitrogen) and 1% Penicillin-Streptomycin (Sigma-Aldrich). All cell lines were verified as authentic through short tandem repeat DNA profile analysis.
| Clinical samples
This study examined samples in tissue arrays of intestinal and diffuse GC tissues constructed and analyzed previously. 27 The tissue arrays 
| Cell treatment and reagents
The following (sources in parentheses) were used: IFN-c (R&D Sys- 
| Flow cytometry
The cells were stained with antibodies as previously described. 28 The following antibodies were used for staining: Annexin V-FITC 
| Gene expression array analysis
Total RNA was isolated using TRIZOL (Invitrogen) and assessed using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific) and Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Microarray gene expression analysis was performed using Illumina HT-12 v4 Expression BeadChips (Illumina, San Diego, CA, USA). The RNA was first biotinylated and amplified using the Illumina TotalPrep-96 RNA Amplification Kit, followed by cDNA synthesis, cDNA purification, cRNA synthesis and cRNA purification.
The samples were then hybridized onto the arrays for 16 hour at 56°C. The arrays were washed and scanned using the Illumina BeadArray Reader. Data were then exported and analyzed using GenomeStudio v2011.11 software (Illumina).
An EMT score was calculated as the average expression level of mesenchymal genes minus the average expression level of epithelial genes from a 76 gene EMT signature. 22, 29 The mRNA expression z- restricted, cancer-testis antigen-specific CTL clone
The human leukocyte antigen (HLA)-A24, LY6K (lymphocyte antigen-6 complex locus K)-peptide-specific CTL clone was established from HLA-A24-positive peripheral blood mononuclear cells from healthy donors as previously described. 8, 33 Briefly, T cells were stimulated with LY6K-peptide-loaded, mitomycin C (Kyowa Hakko Kirin, Tokyo, Japan)-treated autologous mature dendritic cells every 7 days. One week after the third stimulation, the CTL lines were tested for their antigen specificity for the LY6K peptide using the ELISpot assay. A peptide-specific CTL clone was established from an HLA-A24-restricted, LY6K-peptide-specific CTL line using a limiting dilution method.
| Cytotoxicity assay
Cytotoxicity was measured using a calcein-release assay, as previously described. 8, 28 Briefly, target cells were incubated with 5 lmol L À1 of calcein-AM (Dojindo Laboratories, Kumamoto, Japan) for 30 minute at 37°C and 5% CO 2 . Stained targets (5 9 10 3 /well) were co-cultured at various ratios of LY6K-peptide-specific CTL clones in 200 lL of culture medium for 4 hour. Assays were performed in triplicate in a 96-well U-bottomed plate.
After a 4-hour incubation, 100 lL of the supernatant was transferred from the culture plate to a 96-well flat-bottomed plate and the fluorescence of each supernatant was measured at 485-nm excitation and 528-nm emission using an Infinite 200 plate reader (Tecan Group, M€ annedorf, Switzerland).
Spontaneous release was obtained from target cells incubated without effector cells, and maximum release was obtained from detergent-released target cells. The percentage of specific lysis was calculated according to the formula: %specific lysis = 100 9 (experimental release À spontaneous release)/(maximum release À spontaneous release).
| Statistics
Associations between protein expression levels was assessed using already assessed in our previous study. 28 As shown in Figure Table 1 .
Mean age of the patients was 63.6 AE 11.8 years. The majority of patients (n = 128, 85%) were Chinese and 107 (71%) were male.
Mean duration of follow-up was 46.2 AE 44.9 months and a total of 78 (52%) patients had died due to GC at the time of analysis.
Representative patterns of expression of each molecule are shown in Figure 5A .
Because there is no established H-score cutoff to define positive PD-L1, CD3, CD4 and CD8, these molecular features were analyzed as continuous variables. The H-score (mean AE SD) for PD-L1 (tumor membrane) was 53.5 AE 29.1, CD3 (tumor) was 5.8 AE 4.6, CD3 (stroma) was 22.6 AE 12.7, CD4 (tumor) was 0.9 AE 3.3, CD4 (stroma) was 1.1 AE 2.6, CD8 (tumor) was 35.3 AE 22.7 and CD8 (stroma) was 13.6 AE 12.7. PD-L1 levels significantly correlated with CD8 (stroma) levels (P = .018), but not with CD3 nor CD4 in tumor/stroma ( Figure 5B ). PD-L1 levels were also significantly positively correlated with tumor IFN-c levels ( Figure 5C ).
These results are in line with a recent report that upregulation of PD-L1 may result from increased IFN-c production by CTL which migrate to the tumor during immune activation. 38 In the univariate survival analysis, advanced disease stage, CD3
tumor, CD3 stroma and CD8 stroma were significantly associated Tumor, lymph node metastasis and stage are according to the TNM classification for gastric cancer (UICC, 7th edition).
with patient survival, a result similar to those in previously published studies on GC as well as other cancers, 39-41 but PD-L1 alone was not an independent predictor of patient survival (Table 2 ). In a multivariate analysis, considering factors significantly associated with survival in the univariate analysis confirmed that the factors independently associated with survival were advanced disease stage and CD3 stroma ( Table 2 ).
In the analysis of overall survival, progress of disease stage was significantly inversely associated with survival. Furthermore, the survival numbers in the high infiltration group of CD8 stroma, CD3 stroma, CD4 stroma and CD3 tumor were superior to those of the low infiltration group (Figure 6 ).
| DISCUSSION
Interferon gamma is considered to have a double-edge sword effect on anti-tumor immunity, upregulating HLA class I expression and APM components on tumor cells, but also being one of the most potent inducers of PD-L1. 5, 8, 18 There are several reports suggesting that PD-L1 expression on tumor cells in the tumor microenviron- In order to invade, disseminate to distant tissues, and subsequently form metastatic colonies, cancer cells must shift into a more mesenchymal phenotype and this shift can be achieved by EMT. 43 Chen et al 22 We would like to thank Yuka Kimura (Department of Radiation Oncology, Gunma University Graduate School of Medicine) for her technical assistance.
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